Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

[1] Almeida L(2003)Pharmacokinetic and pharmacodynamic profiles of BIA 3–202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects J Clin Pharmacol 43 1350-1360

[2] Soares-da-Silva P(2008)Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson’s disease Clin Neuropharmacol 31 2-18

[3] Ferreira J(2004)Pharmacokinetic-pharmacodynamic interaction between BIA 3–202, a novel COMT inhibitor, and levodopa/carbidopa Clin Neuropharmacol 27 17-24

[4] Almeida L(2003)Pharmacokinetic-pharmacodynamic interaction between BIA 3–202, a novel COMT inhibitor, and levodopa/benserazide Eur J Clin Pharmacol 59 603-609

[5] Cunha L(2001)Managing oral anticoagulant therapy Chest 119 22S-38S

[6] Ticmeanu M(2005)Interaction of warfarin with drugs, natural substances, and foods J Clin Pharmacol 45 127-132

[7] Rosa MM(1976)Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect Clin Pharmacol Ther 19 552-558

[8] Januário C(1996)Clinically important drug interactions with anticoagulants. An update Clin Pharmacokinet 30 416-444

[9] Mitu C-E(1997)A review of enzyme induction of warfarin metabolism with recommendations for patient management Pharmacotherapy 17 917-928

[10] Coelho M(1993)Antiepileptic drugs. A review of clinically significant drug interactions Drug Safety 9 156-184

[1] Almeida L(2003)Pharmacokinetic and pharmacodynamic profiles of BIA 3–202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects J Clin Pharmacol 43 1350-1360

[2] Soares-da-Silva P(2008)Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson’s disease Clin Neuropharmacol 31 2-18

[3] Ferreira J(2004)Pharmacokinetic-pharmacodynamic interaction between BIA 3–202, a novel COMT inhibitor, and levodopa/carbidopa Clin Neuropharmacol 27 17-24

[4] Almeida L(2003)Pharmacokinetic-pharmacodynamic interaction between BIA 3–202, a novel COMT inhibitor, and levodopa/benserazide Eur J Clin Pharmacol 59 603-609

[5] Cunha L(2001)Managing oral anticoagulant therapy Chest 119 22S-38S

[6] Ticmeanu M(2005)Interaction of warfarin with drugs, natural substances, and foods J Clin Pharmacol 45 127-132

[7] Rosa MM(1976)Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect Clin Pharmacol Ther 19 552-558

[8] Januário C(1996)Clinically important drug interactions with anticoagulants. An update Clin Pharmacokinet 30 416-444

[9] Mitu C-E(1997)A review of enzyme induction of warfarin metabolism with recommendations for patient management Pharmacotherapy 17 917-928

[10] Coelho M(1993)Antiepileptic drugs. A review of clinically significant drug interactions Drug Safety 9 156-184